CLEVELAND, OH — The age/sex/gene-expression score (ASGES) test known as Corus CAD (CardioDx) appears easy to incorporate and effective in excluding obstructive coronary artery disease (CAD) in ...

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In stable symptomatic patients with suspected CAD, a precision testing strategy was linked to a 70% ...

Coverage of Blood-Based Test Has Potential to Improve Quality of Care and Lower Costs of Diagnosis of Obstructive Coronary Artery Disease Beyond Traditional Methods PALO ALTO, Calif. – CardioDx, Inc., ...

Dr. Merle C. Turner, Medical Director of Warner Family Practice in Chandler, Arizona, discusses his perspective on the benefits of the CORUS CAD genomic test in determining whether or not a patient ...

CardioDx is touting the results of a new study that showed its Corus CAD molecular diagnostic test for obstructive coronary artery disease can help commercial health insurers save money. The Palo Alto ...

Cardiovascular genomic's specialist Cardiodx Inc.'s test to detect obstructive coronary artery disease (CAD) received long-term validation from a study published in this month's American Heart Journal ...

Scientists at Sanford Burnham Prebys Medical Discovery Institute and the Centro de Biología Molecular Severo Ochoa in Spain have created a test that determines which children with CAD deficiency - a ...